公司进行远期结汇售汇及外汇期权业务遵循稳健原则，不进行以投机和盈利 为目的的外汇交易，所有远期结汇售汇及外汇期权业务均以正常生产经营为基础， 以规避和防范汇率风险为目的。但在进行远期结汇售汇及外汇期权业务时仍会存 在一定的风险： （1）市场风险：在汇率行情走势与预期发生大幅偏离的情况下，公司锁定 北京百普赛斯生物科技股份有限公司 关于公司 2023 年度外汇衍生品投资情况的专项报告 根据《深圳证券交易所创业板上市公司自律监管指南第1号——业务办理》等有 关规定的要求，北京百普赛斯生物科技股份有限公司（以下简称"公司"）董事会 对公司2023年度外汇衍生品投资情况进行了核查，现将相关情况说明如下： 一、外汇衍生品投资审议批准情况 公司于2023年12月4日召开了第二届董事会第五次会议、第二届监事会第五 次会议，审议通过了《关于开展远期结汇售汇及外汇期权业务的议案》，同意公 司以自有资金开展最高合约价值不超过等值人民币20,000万元（含本数）的远期 结汇售汇及外汇期权业务。上述额度自公司董事会审议通过之日起12个月内有 效，在前述额度和期限范围内可循环滚动使用。具体内容详见公司于2023年12月 5日在巨潮资讯 ...

本人张勇，中国国籍，无境外永久居留权，1977 年出生，毕业于日本爱媛大 学分子遗传学专业，博士研究生学历，副教授职称。2001 年 7 月至 2005 年 9 月， 担任陕西科技大学（原西北轻工业学院）生命科学与工程学院助教；2005 年 10 月至 2007 年 9 月，于日本高知大学攻读硕士学位；2007 年 10 月至 2011 年 2 月， 于日本爱媛大学攻读博士学位；2011 年 2 月至 2012 年 12 月担任日本东京大学 医学部微生物系特别研究员；2012 年 12 月至今，担任西南大学资源环境学院讲 师、副教授；2020 年 6 月至今，担任公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 二、2023 年度履职情况 （一）出席董事会及股东大会情况 2023 年度，公司共召开了 9 次董事会，4 次股东大会。本人任职期间，恪尽 职守，详细了解公司运作情况。作为独立董事，基于独立判断的立场，对公司各 项重大事项积极研究分析，发挥独立董事专业优势，严格审核、重点研究重大事 项决策程序的科学性、合理性及对公司的影响。本人对报告 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2024-012 为便于广大投资者更深入全面地了解公司情况，公司定于 2024 年 5 月 15 日 （星期三）下午 15:00-17:00 在全景网举办 2023 年度业绩说明会，本次年度业绩 说明会将采用网络远程的方式举行，投资者可登陆"全景·路演天下" （http://rs.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长、总经理陈宜顶先生，副总经理、董 事会秘书、财务负责人林涛先生，独立董事张勇先生，保荐代表人张远明先生。 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2024 年 5 月 13 日（星期一）17:00 前将关注的问题通过 http://rs.p5w.net 界面的提问 通道进行提问,公司将在 2023 年度业绩说明会上，对投资者普遍关注的问题进行 回答。 欢迎广大投资者积极参与！ 特此公告。 北京百普赛斯生物科技股份有限公司 关于举行 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真 ...

北京百普赛斯生物科技股份有限公司 独立董事工作制度 第一章 总则 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实和勤勉义务。 1 第一条 为进一步完善北京百普赛斯生物科技股份有限公司(以下简称"公司")的治 理结构，促进公司的规范运作，根据《中华人民共和国公司法》(以下简称 "《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")等法律、 法规和规范性文件及《北京百普赛斯生物科技股份有限公司章程》(以下简 称"《公司章程》")的有关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主要股东、 实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立客 观判断的关系的董事。 第四条 公司董事会成员中至少要有三分之一的独立董事，独立董事中至少包括一名 会计专业人士(会计专业人士是指具有高级职称或注册会计师资格的人士)。 独立董事应当按照相关法律、行政法规、中国证券监督管理委员会(以下简 称"中国证监会")、证券交易所和《公司章程》的规定，认真履行职责， 在董事会中发挥参与决策、监督制 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥543.65 million, representing a 14.59% increase compared to ¥474.43 million in 2022 [20]. - The net profit attributable to shareholders decreased by 24.61% to approximately ¥153.59 million in 2023 from ¥203.73 million in 2022 [20]. - The net profit after deducting non-recurring gains and losses was approximately ¥140.40 million, down 23.42% from ¥183.29 million in the previous year [20]. - Cash flow from operating activities decreased by 45.00% to approximately ¥111.20 million in 2023, compared to ¥202.19 million in 2022 [20]. - The total assets at the end of 2023 were approximately ¥2.81 billion, an increase of 2.83% from ¥2.74 billion at the end of 2022 [20]. - The basic earnings per share for 2023 were ¥1.2801, down 24.60% from ¥1.6978 in 2022 [20]. - The company achieved a total sales of recombinant protein products with 3,494 orders in 2023, reflecting a strong market demand [75]. - The company reported a total revenue of 39.218 billion CNY for the year, with a significant increase compared to the previous year [161]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in 2023, representing a 15% year-over-year growth [167]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 9.00 RMB per 10 shares (including tax) to all shareholders, based on a total share capital of 119,726,200 shares after excluding repurchased shares [4]. - The company plans to distribute a cash dividend of RMB 15.00 per 10 shares, totaling RMB 120 million, based on a total share capital of 80 million shares as of December 31, 2022 [185]. - The company plans to distribute a cash dividend of RMB 9.00 per 10 shares, totaling RMB 107,753,580.00 for the year 2023 [189]. - The total cash dividend, including other methods, amounts to RMB 117,751,928.45, which represents 100% of the total distributable profit [189]. - The company's net profit for the year 2023 is reported at RMB 196,907,637.93, with a total distributable profit of RMB 516,270,237.78 [189]. Market Position and Growth Strategy - The company operates in the biotechnology sector, focusing on providing biological reagents and technical services for pharmaceutical companies and research institutions [29]. - The global biopharmaceutical market is projected to grow from $286.4 billion in 2019 to $456.7 billion by 2024, with a compound annual growth rate (CAGR) of 9.8% [30]. - The Chinese biopharmaceutical market is expected to grow from $48 billion in 2019 to $109.6 billion by 2024, with a CAGR of 18.0% [30]. - The company aims to enhance its market competitiveness through domestic production capabilities, improving product quality, and offering better service [36]. - The company is committed to becoming a platform-based cornerstone enterprise in the biopharmaceutical and health industry, providing key biological reagent products and technical services [44]. - The company is focused on expanding its global presence by establishing new overseas subsidiaries and logistics centers to cover the global market comprehensively [128]. - The company aims to deepen its collaboration with existing clients and expand into cell therapy, companion diagnostics, clinical sample analysis, and clinical medication monitoring [128]. Research and Development - The company has established R&D centers in China and the U.S., focusing on innovative technologies such as membrane protein expression and purification, and data-driven optimization techniques [40]. - The company is actively exploring cutting-edge technologies including gene editing and single-molecule detection to lead the recombinant protein industry [40]. - R&D expenses for 2023 amounted to 124.92 million yuan, reflecting a year-on-year increase of 9.72%, with the number of R&D personnel rising to 247, a growth of 30.69% [84]. - The company has developed over 4,500 biological reagent products, including more than 3,400 recombinant proteins, and plans to increase new product development in 2024 [74]. - The company is investing heavily in R&D, with a budget increase of 25% to 150 million for new technologies [167]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements in the annual report, highlighting potential operational risks and corresponding mitigation strategies [4]. - The company has implemented various innovative business models, such as providing bioanalytical testing services and establishing the bioSeedin sub-brand for industry communication [42]. - The company is committed to maintaining high standards in product quality and regulatory compliance, ensuring the reliability of its offerings in the biotechnology sector [49]. - The company has established risk control measures for foreign exchange derivative transactions, focusing on normal production and operational needs [117]. - The company has implemented strict approval procedures for fund allocation and usage to mitigate operational risks [117]. Corporate Governance - The company maintains complete independence from its controlling shareholder in terms of assets, personnel, finance, organization, and business operations [151]. - The company has established an independent financial department with a standardized financial accounting system, ensuring financial operations are separate from the controlling shareholder [152]. - The board of directors operates efficiently, with specialized committees that enhance decision-making processes [149]. - The company has a performance evaluation and incentive mechanism for directors and senior management, aligning with its development status [149]. - The company has approved the 2023 restricted stock incentive plan, which aims to enhance employee motivation and retention [156]. Employee Development and Training - The company has established a comprehensive training system to enhance employee skills across various operational areas [184]. - The employee composition includes 247 technical personnel, 199 sales personnel, and 166 production personnel [181]. - The company has a remuneration policy that aligns employee compensation with market standards and individual performance [182]. - The company aims to enhance talent cultivation and recruitment globally to support its international strategy, ensuring a robust talent pipeline for long-term development [139].

北京百普赛斯生物科技股份有限公司 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据深圳证券交易所《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》的规定，将北京百普赛斯生物科技股份有限公司（以下简称公 司）2023 年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监发行字会[2021]2824 号文《关于同意北京百 普赛斯生物科技股份有限公司首次公开发行股票注册的批复》核准，公司于 2021 年 10 月向社会公开发行人民币普通股（A 股）2,000.00 万股，每股发行价为 112.50 元，应募集资金总额为人民币 225,000.00 万元，根据有关规定扣除发行费用 15,575.92 万元后，实际募集资金金额为 209,424.08 万元。该募集资金已于 2021 年 10 月到账。上述资金到账情况业经容诚会计师事务所（特殊普通合伙）验 ...

关于公司董事、监事、高级管理人员薪酬方案的公告 证券代码：301080 证券简称：百普赛斯 公告编号：2024-008 北京百普赛斯生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开了第二届董事会第六次会议及第二届监事会第六次会议，分别审议通 过了《关于公司<2024 年度董事、高级管理人员薪酬方案>的议案》《关于公司 <2024 年度监事薪酬方案>的议案》，现将相关情况公告如下： 一、适用对象： 公司的董事、监事、高级管理人员。 二、适用期限： 2024 年 1 月 1 日—2024 年 12 月 31 日。 三、薪酬标准 （一）公司董事薪酬方案 1、公司董事在公司担任管理职务者，按照所担任的管理职务领取薪酬；未 担任管理职务的董事，不领取董事津贴。 2、公司独立董事津贴为 10 万元/年（税前）。 （二）公司监事薪酬方案 公司监事薪酬按其在公司管理岗位任职领取报酬外，不领取监事津贴。 （三）公司高级管理人员薪酬方案 公司高级管理人员根据其在公司担任 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2024-004 北京百普赛斯生物科技股份有限公司 第二届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京百普赛斯生物科技股份有限公司（以下简称"公司"）第二届监事会第 六次会议于 2024 年 4 月 23 日下午 14:00 在北京市北京经济技术开发区宏达北 路 8 号公司会议室以现场表决的方式召开。本次会议通知及会议资料于 2024 年 4 月 12 日以专人送达、传真、电子邮件的方式发出，参与现场会议的监事 2 人， 参与通讯会议的监事 1 人，屈文婷女士以通讯方式出席。持续督导机构的保荐代 表人张远明先生列席会议。本次会议由监事会主席屈文婷女士主持，会议的召集、 召开符合法律、法规、规则和《公司章程》规定。 二、监事会会议审议情况 参会的监事认真审议，形成如下决议： （一）审议通过《关于公司<2023 年度监事会工作报告>的议案》 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露的《2023 年度 监事会工作报告》。 表决 ...

Financial Performance - The company reported a revenue of CNY 145,998,736.93 for Q1 2024, representing a 6.67% increase compared to CNY 136,865,462.92 in the same period last year[5]. - Net profit attributable to shareholders decreased by 31.91% to CNY 30,672,071.40 from CNY 45,049,524.12 year-on-year[5]. - The net profit after deducting non-recurring gains and losses also fell by 32.12% to CNY 30,281,879.41 compared to CNY 44,613,402.24 in the previous year[5]. - Basic earnings per share dropped by 31.78% to CNY 0.2561 from CNY 0.3754 in the same period last year[5]. - Total operating revenue for Q1 2024 reached ¥145,998,736.93, an increase of 6.5% compared to ¥136,865,462.92 in Q1 2023[16]. - Net profit for Q1 2024 was ¥29,224,602.63, a decrease of 31.5% from ¥42,917,350.22 in Q1 2023[16]. - The net profit attributable to the parent company for Q1 2024 is ¥30,672,071.40, a decrease of 31.9% from ¥45,049,524.12 in Q1 2023[18]. - The total comprehensive income attributable to the parent company for Q1 2024 is ¥31,533,638.64, down 32.7% from ¥46,893,450.05 in Q1 2023[18]. - The basic earnings per share for Q1 2024 is ¥0.2561, compared to ¥0.3754 in Q1 2023, reflecting a decline of 31.7%[18]. Cash Flow and Investments - The net cash flow from operating activities decreased by 26.59% to CNY 32,062,882.66 from CNY 43,679,158.61 year-on-year[5]. - Cash inflow from operating activities for Q1 2024 is ¥159,651,275.10, an increase of 13.0% from ¥140,542,625.73 in Q1 2023[21]. - The net cash flow from operating activities for Q1 2024 is ¥32,062,882.66, down 26.5% from ¥43,679,158.61 in Q1 2023[21]. - The net cash flow from investing activities for Q1 2024 is -¥98,708,255.26, slightly improved from -¥103,630,241.42 in Q1 2023[21]. - The cash and cash equivalents at the end of Q1 2024 is ¥261,278,982.85, down 30.5% from ¥373,088,562.49 at the end of Q1 2023[22]. - The company received cash from sales of goods and services amounting to ¥159,253,650.42 in Q1 2024, an increase of 13.6% from ¥140,150,234.03 in Q1 2023[20]. - The company reported a cash inflow from financing activities of ¥7,963,431.51 in Q1 2024, compared to a cash outflow of -¥4,323,360.09 in Q1 2023[21]. Costs and Expenses - Total operating costs for Q1 2024 were ¥104,474,301.32, up 23% from ¥85,019,796.15 in the same period last year[16]. - Research and development expenses increased to ¥36,839,838.52, compared to ¥28,785,836.45 in the previous year, reflecting a growth of 28%[16]. - The company paid ¥60,714,503.79 in employee compensation during Q1 2024, which is an increase of 39.7% from ¥43,471,418.88 in Q1 2023[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,812,122,373.31, a slight decrease of 0.05% from CNY 2,813,497,944.62 at the end of the previous year[5]. - Cash and cash equivalents at the end of Q1 2024 were ¥1,863,948,516.91, down from ¥1,984,141,692.09 at the beginning of the quarter[13]. - Inventory increased to ¥154,485,417.75 from ¥136,718,199.30, indicating a growth of 12.9%[14]. - Short-term borrowings rose significantly to ¥30,500,000.00 from ¥6,008,825.75, marking an increase of over 408%[15]. - Total liabilities decreased to ¥191,174,308.35 from ¥225,224,851.67, a reduction of approximately 15.1%[15]. - The company's equity attributable to shareholders increased to ¥2,623,680,707.09 from ¥2,589,558,266.31, reflecting a growth of 1.3%[15]. - Shareholders' equity attributable to the parent company increased by 1.32% to CNY 2,623,680,707.09 from CNY 2,589,558,266.31 at the end of the previous year[5]. Market and Strategic Insights - The decline in net profit is attributed to slower revenue growth and increased investments in overseas market expansion and R&D, with benefits not yet realized[8]. - The company received government subsidies amounting to CNY 397,624.68 during the reporting period[7].

| | | | | | 1、《关于公司<2023年半年度报告全文及其摘要> | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | 的议案》 | | | | | | | | 2、《关于公司<2023年半年度募集资金存放与使用 | | | | | | | 第二届监 | 情况的专项报告>的议案》 | | | 2023 | | 年 | 8 | 事会第二 | 3、《关于调整2022年限制性股票激励计划首次及 | 审议 | | 月 | 25 | 日 | | 次会议 | 预留授予价格及授予数量的议案》 | 通过 | | | | | | | 4、《关于2022年限制性股票首次授予部分第一个 | | | | | | | | 归属期归属条件未成就并作废部分已授予但尚未 | | | | | | | | 归属的限制性股票的议案》 | | | | | | | | 1、《关于公司<2023年限制性股票激励计划（草案）> | | | | | | | 第二届监 | 及其摘要的议案》 | | | 2023 | | 年 | 9 | 事会第三 | 2、《关于公司<2023年限制性股 ...